Abstract
For many patients, early detection of cancer strongly correlates with better outcomes. Unfortunately, the cancers with the poorest 5-year survival statistics are those that are most often found at late stages. Correlation between outcomes and detection may justify broad cancer screening if innovative approaches provide compelling results with acceptable performance for general screening or early detection purposes. Several diagnostic companies test blood products to identify markers for disease, e.g.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
